Current MedTech product development methods are falling short of meeting the rising demand for rapid therapeutic solutions that are safe, effective and withstand stringent regulatory scrutiny.
During the past decade, the FDA has been exploring and advocating for the increased use of Computational Modeling & Simulation (CM&S). However, there have also been obstacles in leveraging CM&S to its fullest potential. Beyond the agency’s ongoing development of CM&S regulatory review processes, medical device manufacturers face their own roadblocks in adopting CM&S technology due to legacy processes, vendor selection, and implementation decisions.
Unified Modeling and Simulation (MODSIM) from Dassault Systèmes is providing a new paradigm for improving collaboration, process efficiencies and left shifting the value of simulation into the design process.
In this presentation, learn how to easily implement a virtual (in silico) MODSIM approach to better manage the conflicting needs for usability, engineering, manufacturability, and cost.